Pratik Chandrani
Overview
Explore the profile of Pratik Chandrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yadav N, Sunder R, Desai S, Dharavath B, Chandrani P, Godbole M, et al.
Breast Cancer Res
. 2022 Dec;
24(1):97.
PMID: 36578092
Background: A preoperative-progesterone intervention increases disease-free survival in patients with breast cancer, with an unknown underlying mechanism. We elucidated the role of non-coding RNAs in response to progesterone in human...
12.
George I, Sathe G, Ghose V, Chougule A, Chandrani P, Patil V, et al.
Front Cell Dev Biol
. 2022 Nov;
10:957983.
PMID: 36393868
Tongue squamous cell carcinoma is an aggressive oral cancer with a high incidence of metastasis and poor prognosis. Most of the oral cavity cancer patients present in clinics with locally...
13.
Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, et al.
Nat Commun
. 2022 Sep;
13(1):5312.
PMID: 36085288
Response to immunotherapies can be variable and unpredictable. Pathology-based phenotyping of tumors into 'hot' and 'cold' is static, relying solely on T-cell infiltration in single-time single-site biopsies, resulting in suboptimal...
14.
Lung cancer with dual and driver alterations at baseline: a retrospective observational cohort study
Noronha V, Chougule A, Chandrani P, Kaushal R, Patil V, Menon N, et al.
Acta Oncol
. 2022 Aug;
61(9):1143-1147.
PMID: 35972844
No abstract available.
15.
Panda G, Noronha V, Shah D, John G, Chougule A, Patil V, et al.
Ecancermedicalscience
. 2022 Aug;
16:1385.
PMID: 35919239
Introduction: Limited data exists for non-small cell lung cancer (NSCLC) patients harbouring T790M mutation. Methods: NSCLC patients, with T790M, who registered at our institute between 01/03/2015 and 31/12/2019, were considered...
16.
Behel V, Noronha V, Choughule A, Shetty O, Chandrani P, Kapoor A, et al.
JCO Glob Oncol
. 2022 Jul;
8:e2200030.
PMID: 35802838
Purpose: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was...
17.
Behel V, Chougule A, Noronha V, Patil V, Menon N, Singh A, et al.
Clin Lung Cancer
. 2022 Jun;
23(5):410-418.
PMID: 35649817
Introduction: Plasma cfDNA-based mutation analysis has shown disease-monitoring potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation testing as a monitoring tool in patients with NSCLC. Patients...
18.
Chougule A, Jagtap V, Nikam A, Kale S, Nambiar K, Bagayatkar P, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626446
The speed, accuracy, and increasing affordability of next-generation sequencing (NGS) have revolutionized the advent of precision medicine. To date, standardized validation criteria for diagnostic accreditation do not exist due to...
19.
Agrawal A, Noronha V, Patil V, Menon N, Kapoor A, Chougule A, et al.
Indian J Surg Oncol
. 2022 Apr;
13(1):68-80.
PMID: 35462658
Thyroid cancer is the most common endocrine malignancy. While surgery remains the mainstay of the treatment of all different histologies, for differentiated thyroid cancers, radioactive iodine also plays an important...
20.
Desai S, Dharavath B, Manavalan S, Rane A, Redhu A, Sunder R, et al.
NAR Cancer
. 2022 Mar;
4(1):zcac006.
PMID: 35252868
Persistent pathogen infection is a known cause of malignancy, although with sparse systematic evaluation across tumor types. We present a comprehensive landscape of 1060 infectious pathogens across 239 whole exomes...